Insights from a cross-sectional population-based study of 10,929 Australians living with Parkinson's disease: risk factors, comorbidities, and sex differences.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41970459.
- Also identified by DOI 10.1016/j.lanwpc.2026.101816 and PMC identifier 13069442.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The pathogenesis of Parkinson's disease (PD) remains incompletely understood; large-scale studies are needed to further elucidate its genetic and environmental underpinnings. The Australian Parkinson's Genetics Study (APGS) is an ongoing nationwide, population-based initiative established to advance understanding of PD determinants and progression. We present a cross-sectional characterisation of 10,929 participants with self-reported PD recruited across Australia through assisted mail-outs, media outreach, and digital engagement. Participants complete comprehensive questionnaires capturing sociodemographic, clinical, environmental, lifestyle, and behavioural data, and provide saliva samples for genetic analysis. A control cohort is currently being recruited and not reported here. The cohort is 63% male, with a mean age of 71 years and symptom onset at 64 years; 79% report diagnosis by a neurologist and 25% report a family history. Non-motor symptoms and neuropsychiatric comorbidities are common, including sleep disturbances, memory changes, and depression, alongside risk factors such as pesticide exposure (36%), traumatic brain injury (16%), and high-risk occupations (33%). Sex-based differences are evident: females more frequently report unilateral onset (81% vs 75%), falls (45% vs 41%), and pain (70% vs 63%), whereas males report higher rates of memory changes (67% vs 61%), pesticide exposure (42% vs 28%), high-risk occupations (44% vs 16%), and impulsive control behaviour, such as sexual behaviour (56% vs 19%). Leveraging APGS, the largest active PD cohort globally, our findings highlight the clinical and risk heterogeneity of PD and the importance of sex-specific research and care. The study's successful recruitment demonstrates the feasibility of large-scale remote enrolment, while its comprehensive design and ongoing expansion, including genomic profiling and digital phenotyping, position APGS as a transformative platform for advancing PD risk prediction, biomarker discovery, and therapeutic development. APGS is supported by the Global Parkinson's Genetics Program (GP2), Shake It Up Australia Foundation, and Michael J. Fox Foundation for Parkinson's Research (MJFF-021952).